Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation
Non-small Cell Lung Cancer
DRUG: Icotinib
progression-free survival, 10 months
tumor response rate, 2 months|overall survival, 24 months
This study aims to evaluate the efficacy of icotinib, a first generation EGFR TKI, in non-small cell lung cancer patients harboring uncommon EGFR mutation